Feds Closer To Dx Distinguishing Zika From Dengue As HHS Tries To Plug Funding Gap

The US Department of Health and Human Services gave up on getting new funding from Congress in 2016 to fight Zika virus, and instead juggled its budget this week to throw $81m at the Zika vaccine effort. And while there has been headway on a test to differentiate Zika from Dengue, HHS Secretary Burwell told House Minority Leader Nancy Pelosi in an Aug. 11 letter that NIH currently lacks funds to support diagnostics and other Zika priorities.

The US Department of Health and Human Services has had to dig deep into its own budget, diverting dollars from cancer and diabetes research, to funnel $81m more to NIH and the Biomedical Advanced Research and Development Authority (BARDA) to carry out work on a Zika virus vaccine, NIH's Anthony Fauci confirmed at an Aug. 11 briefing led by several government, state and local officials in Washington, DC. However, the funding supplement does not include additional needed dollars to support diagnostics development.

The secretary had been hoping for additional funding from Congress to fight the virus, but the House and Senate reached...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from United States

  • Global Medtech Guidance Tracker: September 2024

     
    • By 

    Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.

  • Senseonics Readies For US Launch Of 'World’s First One-Year CGM'

     

    US FDA has greenlighted Senseonics’ Eversense 365 continuous glucose monitor, which must be replaced just once a year. Capable of being integrated with compatible insulin pumps as part of an automated insulin delivery system, the fully implantable device lasts 185 days longer than the Eversense E3 sensor and far outstrips competing CGMs, which last only for 10-14 days.

  • Does SCOTUS Chevron Decision Tip The Scales In Favor Of Industry?

     

    With the reversal of the Chevron doctrine in June, lower courts will now have more say in deciding regulatory statutes when the language is murky. But will that open the door to more legal challenges from the healthcare industry against government regulations it finds unfavorable? A pair of legal experts recently discussed the potential implications of the Court’s decision.

  • FDA Releases Six More De Novo Summaries

     
    • By 

    The US FDA released six more device classifications in early September, including products from Edwards, Interscope, and Baxter Healthcare.

More from North America